Enosis, OVID and the MIND Foundation are launching an in-clinic pilot offering of psychedelic-augmented psychotherapy that will leverage Virtual Reality (VR) technology.
Verywell Mind has carried out a survey, revealing that one in three Americans who are currently in therapy are willing to try psychedelics to help with...
Cybin has announced the graduation of highly-skilled facilitators from its EMBARK Psychedelic-Assisted Psychotherapy Training Program.
The University of Guelph (UoG) has announced that it is one of the first universities to be granted a licence by Health Canada to cultivate psychedelic...
A researcher at Cornell University is using optical microscopy and other tools to map the brain’s neural response to psychedelics.
Awakn’s wholly-owned subsidiary, Awakn Oslo AS, has entered into a debt financing agreement with TD Veen AS, a family-owned, Norwegian investment company and current shareholder of...
Algernon Pharmaceuticals has entered an Investigator-Initiated Clinical Trial Agreement with Yale University to investigate multiple intravenous doses of DMT for the treatment of depression.
Beckley Psytech has entered into a definitive agreement to acquire clinical-stage life science company, Eleusis Therapeutics Limited, in an all-equity transaction.
HMNC Brain Health has raised €14.3m in a funding series, raised from existing investors, including Carsten Maschmeyer, the Jahr Group and Guntard Gutmann.
Small Pharma has had its second United States patent granted by the United States Patent Office.